Fenofibrate and renal disease: Clinical effects in diabetes

Clinical Lipidology

Volumn 8, Issue 6, 2013, Pages 669-680

  Ting, Ru Dee ^a,b   Keech, Anthony ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

albuminuria; cardiovascular risk; creatinine; diabetes; estimated glomerular filtration rate; fenofibrate; FIELD; nephropathy; renal

Indexed keywords

BEZAFIBRATE; CIMETIDINE; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FENOFIBRATE; GEMFIBROZIL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PLACEBO; PRAVASTATIN; SIMVASTATIN; TRIMETHOPRIM; VERY LOW DENSITY LIPOPROTEIN;

ALBUMINURIA; AMINOACIDEMIA; CENTRAL NERVOUS SYSTEM DISEASE; CREATINEMIA; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DRUG DOSE REDUCTION; DRUG MECHANISM; DYSLIPIDEMIA; END STAGE RENAL DISEASE; ERECTILE DYSFUNCTION; GALLBLADDER DISEASE; GASTROINTESTINAL SYMPTOM; GLOMERULUS FILTRATION RATE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; KIDNEY DISEASE; LUNG EMBOLISM; MACROALBUMINURIA; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREATITIS; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL PROTECTION; REVIEW; RHABDOMYOLYSIS; SKIN DISEASE; SYSTEMATIC REVIEW; THROMBOEMBOLISM;

EID: 84889584077     PISSN: 17584299     EISSN: 17584302     Source Type: Journal    
DOI: 10.2217/clp.13.69     Document Type: Review

References (93)

1. Munoz A, Guichard JP, Reginault P. Micronised fenofibrate. Atherosclerosis 110(Suppl.) S45-S48 (1994
2. Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347, 645-650 (1990
3. Vijayaraghavan K. Treatment of dyslipidemia in patients with Type 2 diabetes. Lipids Health Dis. 9, 144 (2010
4. Keech AC, Mitchell P, Summanen PA et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): A randomised controlled trial. Lancet 370, 1687-1697 (2007 (Pubitemid 350100775)
5. Rajamani K, Colman PG, Li LP et al. Effect of fenofibrate on amputation events in people with Type 2 diabetes mellitus (FIELD study): A prespecified analysis of a randomised controlled trial. Lancet 373, 1780-1788 (2009
6. The ACCORD Study Group and ACCORD Eye Study Group. Effects of medical therapies on retinopathy progression in Type 2 diabetes. N. Engl. J. Med. 363, 233-244 (2010
7. The FIELD Study Investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with Type 2 diabetes mellitus (the FIELD study): Randomised controlled trial. Lancet 366, 1849-1861 (2005
8. Ansquer JC, Foucher C, Rattier S, Taskinen MR, Steiner G. Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in Type 2 diabetes: Results from the Diabetes Atherosclerosis Intervention Study (DAIS). Am. J. Kidney Dis. 45, 485-493 (2005 (Pubitemid 40341327)
9. Davis T, Ting R, Best J et al. Effects of fenofibrate on renal function in patients with Type 2 diabetes mellitus: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetologia 54, 280-290 (2011)
10. Mychaleckyj JC, Craven T, Nayak U et al. Reversibility of fenofibrate therapy-induced renal function impairment in ACCORD Type 2 diabetic participants. Diabetes Care 35, 1008-1014 (2012
11. Guan Y, Breyer MD. Peroxisome proliferatoractivated receptors (PPARs): Novel therapeutic targets in renal disease. Kidney Int. 60, 14-30 (2001 (Pubitemid 32587535)
12. Braissant O, Foufelle F, Scotto C, Dauca M, Wahli W. Differential expression of peroxisome proliferator-activated receptors (PPARs): Tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology 137, 354-366 (1996 (Pubitemid 26005011)
13. Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: Nuclear control of metabolism. Endocr. Rev. 20, 649-688 (1999 (Pubitemid 30650602)
14. Keating GM, Croom KF. Fenofibrate: A review of its use in primary dyslipidaemia, the metabolic syndrome and Type 2 diabetes mellitus. Drugs 67, 121-153 (2007 (Pubitemid 46105094)
15. Fazio S, Linton MF. The role of fibrates in managing hyperlipidemia: Mechanisms of action and clinical efficacy. Curr. Atheroscler. Rep. 6, 148-157 (2004
16. Escher P, Wahli W. Peroxisome proliferatoractivated receptors: Insight into multiple cellular functions. Mutat. Res. 448, 121-138 (2000 (Pubitemid 30139449)
17. Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 98, 2088-2093 (1998 (Pubitemid 28512236)
18. Zambon A, Gervois P, Pauletto P, Fruchart JC, Staels B. Modulation of hepatic inflammatory risk markers of cardiovascular diseases by PPAR-alpha activators: Clinical and experimental evidence. Arterioscler. Thromb. Vasc. Biol. 26, 977-986 (2006 (Pubitemid 43732101)
19. Rosenson RS, Huskin AL, Wolff DA, Helenowski IB, Rademaker AW. Fenofibrate reduces fasting and postprandial inflammatory responses among hypertriglyceridemia patients with the metabolic syndrome. Atherosclerosis 198, 381-388 (2008
20. Fruchart JC. Peroxisome proliferator-activated receptor-alpha (PPAR[alpha]): At the crossroads of obesity, diabetes and cardiovascular disease. Atherosclerosis 205, 1-8 (2009
21. Playford DA, Watts GF, Best JD, Burke V. Effect of fenofibrate on brachial artery flowmediated dilatation in Type 2 diabetes mellitus. Am. J. Cardiol. 90, 1254-1257 (2002 (Pubitemid 35346887)
22. Capell WH, DeSouza CA, Poirier P et al. Short-term triglyceride lowering with fenofibrate improves vasodilator function in subjects with hypertriglyceridemia. Arterioscler. Thromb. Vasc. Biol. 23, 307-313 (2003 (Pubitemid 36231945)
23. Koh KK, Han SH, Quon MJ, Yeal Ahn J, Shin EK. Beneficial effects of fenofibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hypertriglyceridemia. Diabetes Care 28, 1419-1424 (2005 (Pubitemid 40756707)
24. Tsimihodimos V, Liberopoulos E, Elisaf M. Pleiotropic effects of fenofibrate. Curr. Pharm. Des. 15, 517-528 (2009
25. Marx N, Kehrle B, Kohlhammer K et al. PPAR activators as anti-inflammatory mediators in human T lymphocytes: Implications for atherosclerosis and transplantation-associated arteriosclerosis. Circ. Res. 90, 703-710 (2002 (Pubitemid 34640890)
26. Delerive P, De Bosscher K, Besnard S et al. Peroxisome proliferator-activated receptor a negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kB and AP-1. J. Biol. Chem. 274, 32048-32054 (1999). Review | Ting & Keech future science group www.futuremedicine.com 679
27. Chen Y, Hu Y, Lin M et al. Therapeutic effects of PPARa agonists on diabetic retinopathy in Type 1 diabetes models. Diabetes 62(1), 261-272 (2013
28. Kim J, Ahn JH, Kim JH et al. Fenofibrate regulates retinal endothelial cell survival through the AMPK signal transduction pathway. Exp. Eye Res. 84, 886-893 (2007 (Pubitemid 46590130)
29. Muntner P, Coresh J, Smith JC, Eckfeldt J, Klag MJ. Plasma lipids and risk of developing renal dysfunction: The Atherosclerosis Risk in Communities study. Kidney Int. 58, 293-301 (2000 (Pubitemid 30429874)
30. Anami Y, Kobori S, Sakai M et al. Human beta-migrating very low density lipoprotein induces foam cell formation in human mesangial cells. Atherosclerosis 135, 225-234 (1997 (Pubitemid 28015189)
31. Balakumar P, Kadian S, Mahadevan N. Are PPAR alpha agonists a rational therapeutic strategy for preventing abnormalities of the diabetic kidney? Pharmacol. Res. 65, 430-436 (2012)
32. Agouridis AP, Kostapanos MS, Tsimihodimos V et al. Effect of rosuvastatin monotherapy or in combination with fenofibrate or omega-3 fatty acids on lipoprotein subfraction profile in patients with mixed dyslipidaemia and metabolic syndrome. Int. J. Clin. Pract. 66, 843-853 (2012
33. Jong MC, Hofker MH, Havekes LM. Role of apoCs in lipoprotein metabolism: Functional differences between apoC1, apoC2, and apoC3. Arterioscler. Thromb. Vasc. Biol. 19, 472-484 (1999 (Pubitemid 29135144)
34. Portilla D. Energy metabolism and cytotoxicity. Semin. Nephrol. 23, 432-438 (2003 (Pubitemid 37176688)
35. Kouroumichakis I, Papanas N, Zarogoulidis P, Liakopoulos V, Maltezos E, Mikhailidis DP. Fibrates: Therapeutic potential for diabetic nephropathy? Eur. J. Intern. Med. 23, 309-316 (2012
36. Marx N, Duez H, Fruchart J-C, Staels B. Peroxisome proliferator-activated receptors and atherogenesis: Regulators of gene expression in vascular cells. Circ. Res. 94, 1168-1178 (2004 (Pubitemid 38656403)
37. Barbier O, Torra IP, Duguay Y et al. Pleiotropic actions of peroxisome proliferatoractivated receptors in lipid metabolism and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 22, 717-726 (2002 (Pubitemid 34517781)
38. Idzior-Walus B, Sieradzki J, Rostworowski W et al. Effects of comicronised fenofibrate on lipid and insulin sensitivity in patients with polymetabolic syndrome X. Eur. J. Clin. Invest. 30, 871-878 (2000
39. Varghese Z, Moorhead JF, Ruan XZ. The PPAR[alpha] ligand fenofibrate: Meeting multiple targets in diabetic nephropathy. Kidney Int. 69, 1490 (2006
40. Kim H, Haluzik M, Asghar Z et al. Peroxisome proliferator-activated receptoralpha agonist treatment in a transgenic model of Type 2 diabetes reverses the lipotoxic state and improves glucose homeostasis. Diabetes 52, 1770-1778 (2003 (Pubitemid 36792469)
41. Tziomalos K, Athyros VG, Karagiannis A, Mikhailidis DP. Anti-inflammatory effects of fibrates: An overview. Curr. Med. Chem. 16, 676-684 (2009
42. The ACCORD Study Group. Effects of combination lipid therapy in Type 2 diabetes mellitus. N. Engl. J. Med. 362, 1563-1574 (2010
43. Bonds DE, Craven TE, Buse J et al. Fenofibrate-associated changes in renal function and relationship to clinical outcomes among individuals with Type 2 diabetes: The Action to Control Cardiovascular Risk in Diabetes (ACCORD) experience. Diabetologia 55, 1641-1650 (2012
44. Diabetes Atherosclerosis Intervention Study Investigators. Effect of fenofibrate on progression of coronary-artery disease in Type 2 diabetes: The Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 357, 905-910 (2001
45. Nagai T, Tomizawa T, Nakajima K, Mori M. Effect of bezafibrate or pravastatin on serum lipid levels and albuminuria in NIDDM patients. J. Atheroscler. Thromb. 7, 91-96 (2000
46. Bruce R, Daniels A, Cundy T. Renal function changes in diabetic nephropathy induced by bezafibrate. Nephron 73, 490 (1996 (Pubitemid 26229709)
47. Smulders YM, van Eeden AE, Stehouwer CD, Weijers RN, Slaats EH, Silberbusch J. Can reduction in hypertriglyceridaemia slow progression of microalbuminuria in patients with non-insulin-dependent diabetes mellitus? Eur. J. Clin. Invest. 27, 997-1002 (1997 (Pubitemid 28012621)
48. Ansquer JC, Dalton RN, Causse E, Crimet D, Malicot KL, Foucher C. Effect of fenofibrate on kidney function: A 6-week randomized crossover trial in healthy people. Am. J. Kidney Dis. 51, 904-913 (2008 (Pubitemid 351697561)
49. Chapman MJ. Fibrates: Therapeutic review. Br. J. Diabetes Vasc. Dis. 6, 11-19 (2006
50. Hottelart C, El Esper N, Rose F, Achard JM, Fournier A. Fenofibrate increases creatinemia by increasing metabolic production of creatinine. Nephron 92, 536-541 (2002
51. Tsimihodimos V, Bairaktari E, Elisaf M. Fibrate-induced increase in serum urea and creatinine levels. Nephrol. Dial. Transplant. 17, 682; author reply 682 (2002 (Pubitemid 34308831)
52. Tsimihodimos V, Kakafika A, Elisaf M. Fibrate treatment can increase serum creatinine levels. Nephrol. Dial. Transplant. 16, 1301 (2001 (Pubitemid 32547398)
53. Lipscombe J, Lewis GF, Cattran D, Bargman JM. Deterioration in renal function associated with fibrate therapy. Clin. Nephrol. 55, 39-44 (2001 (Pubitemid 32041781)
54. Devuyst O, Goffin E, Pirson Y, van Ypersele de Strihou CH. Creatinine rise after fibrate therapy in renal graft recipients. Lancet 341, 840 (1993 (Pubitemid 23096336)
55. Broeders N, Knoop C, Antoine M, Tielemans C, Abramowicz D. Fibrate-induced increase in blood urea and creatinine: Is gemfibrozil the only innocuous agent? Nephrol. Dial. Transplant. 15, 1993-1999 (2000
56. Perrone RD, Madias NE, Levey AS. Serum creatinine as an index of renal function: New insights into old concepts. Clin. Chem. 38, 1933-1953 (1992
57. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Ann. Intern. Med. 130, 461-470 (1999 (Pubitemid 29135798)
58. Levey AS, Stevens LA, Schmid CH et al. A new equation to estimate glomerular filtration rate. Ann. Intern. Med. 150, 604-612 (2009
59. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 16, 31-41 (1976
60. Fontser N, Salinas I, Bonal J et al. Are prediction equations for glomerular filtration rate useful for the long-term monitoring of Type 2 diabetic patients? Nephrol. Dial. Transplant. 21, 2152-2158 (2006 (Pubitemid 44295039)
61. Chudleigh RA, Dunseath G, Evans W et al How reliable is estimation of glomerular filtration rate at diagnosis of Type 2 diabetes? Diabetes Care 30, 300-305 (2007 (Pubitemid 46198334)
62. Rule AD, Larson TS, Bergstralh EJ, Slezak JM, Jacobsen SJ, Cosio FG. Using serum creatinine to estimate glomerular filtration rate: Accuracy in good health and in chronic kidney disease. Ann. Intern. Med. 141, 929-937 (2004
63. Levey AS. Measurement of renal function in chronic renal disease. Kidney Int. 38, 167-184 (1990 (Pubitemid 20209447)
64. Toffaletti JG, McDonnell EH. Variation of serum creatinine, cystatin C, and creatinine clearance tests in persons with normal renal Fenofibrate & renal disease: Clinical effects in diabetes future science group function. Clin. Chim. Acta 395, 115-119 (2008
65. Hilbrands LB, Artz MA, Wetzels JF, Koene RA. Cimetidine improves the reliability of creatinine as a marker of glomerular filtration. Kidney Int. 40, 1171-1176 (1991
66. Yamazaki M, Li B, Louie SW et al. Effects of fibrates on human organic anion-transporting polypeptide 1B1-, multidrug resistance protein 2- And P-glycoprotein-mediated transport. Xenobiotica 35, 737-753 (2005 (Pubitemid 41441523)
67. Forsblom C, Hiukka A, Leinonen E, Sundvall J, Groop PH, Taskinen M-R. Effects of long-term fenofibrate treatment on markers of renal function in Type 2 diabetes: FIELD Helsinki substudy. Diabetes Care 33, 215-220 (2010
68. Hottelart C, Esper NE, Achard JM, Pruna A, Fournier A. Fenofibrate increases blood creatinine, but does not change the glomerular filtration rate in patients with mild renal insufficiency. Nephrologie 20, 41-44 (1999 (Pubitemid 29091030)
69. Levin A, Duncan L, Djurdjev O et al. A randomized placebo-controlled double-blind trial of lipid-lowering strategies in patients with renal insufficiency: Diet modification with or without fenofibrate. Clin. Nephrol. 53, 140-146 (2000 (Pubitemid 30082248)
70. Chen Y-J, Quilley J. Fenofibrate treatment of diabetic rats reduces nitrosative stress, renal cyclooxygenase-2 expression, and enhanced renal prostaglandin release. J. Pharmacol. Exper. Ther. 324, 658-663 (2008 (Pubitemid 351185835)
71. Abrahamson M, Olafsson I, Palsdottir A et al. Structure and expression of the human cystatin C gene. Biochem. J. 268, 287-294(1990 (Pubitemid 20193964)
72. Reed CH. Diagnostic applications of cystatin C. Br. J. Biomed. Sci. 57, 323-329 (2000 (Pubitemid 32099397)
73. Sjtr P, Tidman M, Jones I. Determination of the production rate and non-renal clearance of cystatin C and estimation of the glomerular filtration rate from the serum concentration of cystatin C in humans. Scand. J. Clin. Lab. Invest. 65, 111-124 (2005 (Pubitemid 40571147)
74. Knight EL, Verhave JC, Spiegelman D et al. Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int. 65, 1416-1421 (2004 (Pubitemid 38406982)
75. Mandard S, Mler M, Kersten S. Peroxisome proliferator-activated receptor a target genes. Cell. Mol. Life Sci. 61, 393-416 (2004 (Pubitemid 38316578)
76. Schiffrin EL. Peroxisome proliferatoractivated receptors and cardiovascular remodeling. Am. J. Physiol. Heart Circ. Physiol. 288, H1037-H1043 (2005 (Pubitemid 40270004)
77. Guidi E, Minetti EE, Cozzi MG. Acute and long-term effects of ACE inhibition on renal haemodynamics in glomerular and interstitial nephropathies. J. Renin Angiotensin Aldosterone Syst. 3, 40-45 (2002 (Pubitemid 34467701)
78. Ruggenenti P, Cravedi P, Remuzzi G. The RAAS in the pathogenesis and treatment of diabetic nephropathy. Nat. Rev. Nephrol. 6, 319-330 (2010
79. Bakris GL, Weir MR. Angiotensinconverting enzyme inhibitor-associated elevations in serum creatinine. Is this a cause for concern? Arch. Intern. Med. 160, 685-693 (2000 (Pubitemid 30140419)
80. Tonelli M, Gill J, Pandeya S, Bohm C, Levin A, Kiberd BA. Barriers to blood pressure control and angiotensin enzyme inhibitor use in Canadian patients with chronic renal insufficiency. Nephrol. Dial. Transplant. 17, 1426-1433 (2002
81. Holtkamp FA, de Zeeuw D, Thomas MC et al. An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function. Kidney Int. 80, 282-287 (2011
82. Hemmelgarn BR, Manns BJ, Lloyd A et al. Relation between kidney function, proteinuria, and adverse outcomes. JAMA 303, 423-429 (2010
83. Ninomiya T, Perkovic V, de Galan B et al. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J. Am. Soc. Nephrol. 20, 1813-1821 (2009
84. Shahinfar S, Dickson T, Zhang Z, Keane WF, Brenner BM, for the RENAAL Investigators. Baseline predictors of end-stage renal disease risk in patients with Type 2 diabetes and nephropathy: New lessons from the RENAAL Study. Kidney Int. 67, S48-S51 (2005
85. Ting RD, Keech AC, Drury PL et al. Benefits and safety of long-term fenofibrate therapy in people with Type 2 diabetes and renal impairment: The FIELD Study. Diabetes Care 35, 218-225 (2012
86. Davidson MH, Armani A, McKenney JM, Jacobson TA. Safety considerations with fibrate therapy. Am. J. Cardiol. 99, S3-S18 (2007 (Pubitemid 46412226)
87. Holoshitz N, Alsheikh-Ali AA, Karas RH. Relative safety of gemfibrozil and fenofibrate in the absence of concomitant cerivastatin use. Am. J. Cardiol. 101, 95-97 (2008
88. Kostapanos MS, Florentin M, Elisaf MS. Fenofibrate and the kidney: An overview. Eur. J. Clin. Invest. 43, 522-531 (2013
89. Chapman MJ. Pharmacology of fenofibrate. Am. J. Med. 83, 21-25 (1987
90. Harper CR, Jacobson TA. Managing dyslipidemia in chronic kidney disease. J. Am. Coll. Cardiol. 51, 2375-2384 (2008 (Pubitemid 351815163)
91. K/DOQI. K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease. Am. J. Kidney Dis. 41, I-IV, S1-S91 (2003
92. McPherson R, Frohlich J, Fodor G, Genest J, Canadian Cardiovascular S. Canadian Cardiovascular Society position statement - recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. Can. J. Cardiol. 22, 913-927 (2006 (Pubitemid 44596492)
93. Sica D. Fibrate therapy and renal function. Curr. Atherosclerosis Rep. 11, 338-342 (2009)